Difficulty: Medium
Average Score: 66%
Practice
Which rationale describes treatment of atopic allergies with immunotherapy?
Correct answer
C
Rationale
The correct answer is C) It stimulates increased IgG to bind with allergen-reactive sites, preventing mast cell-bound IgE reactions.
Explanation:
Immunotherapy for atopic allergies involves introducing increasing doses of allergen to the patient to desensitize their immune system. This process aims to stimulate the production of allergen-specific IgG antibodies that compete with IgE antibodies for allergen binding sites. By binding to these sites, IgG prevents the allergen from triggering mast cell degranulation and the release of inflammatory mediators, thus reducing allergic reactions.
Why others are wrong:
A) Decreasing levels of allergen-specific T helper cells (Option A) does not directly address the mechanism of action of immunotherapy for atopic allergies.
B) Decreasing the level of IgE (Option B) is not the primary goal of immunotherapy; the focus is on increasing IgG levels to outcompete IgE for allergen binding.
D) Gradually increasing the amount of allergen in the body (Option D) is correct in principle, but the key factor in immunotherapy success is the production of allergen-specific IgG, not the allergen's recognition by the body.
Educational context:
Understanding the rationale behind immunotherapy for atopic allergies is crucial for pharmacology students and healthcare professionals. It demonstrates the practical application of immunological principles in treating allergic conditions and highlights the importance of inducing a shift from an IgE-mediated response to an IgG-mediated response to allergens. This knowledge helps in providing effective patient care and managing allergic diseases more efficiently.
Explanation:
Immunotherapy for atopic allergies involves introducing increasing doses of allergen to the patient to desensitize their immune system. This process aims to stimulate the production of allergen-specific IgG antibodies that compete with IgE antibodies for allergen binding sites. By binding to these sites, IgG prevents the allergen from triggering mast cell degranulation and the release of inflammatory mediators, thus reducing allergic reactions.
Why others are wrong:
A) Decreasing levels of allergen-specific T helper cells (Option A) does not directly address the mechanism of action of immunotherapy for atopic allergies.
B) Decreasing the level of IgE (Option B) is not the primary goal of immunotherapy; the focus is on increasing IgG levels to outcompete IgE for allergen binding.
D) Gradually increasing the amount of allergen in the body (Option D) is correct in principle, but the key factor in immunotherapy success is the production of allergen-specific IgG, not the allergen's recognition by the body.
Educational context:
Understanding the rationale behind immunotherapy for atopic allergies is crucial for pharmacology students and healthcare professionals. It demonstrates the practical application of immunological principles in treating allergic conditions and highlights the importance of inducing a shift from an IgE-mediated response to an IgG-mediated response to allergens. This knowledge helps in providing effective patient care and managing allergic diseases more efficiently.